Asieris MediTech of Taizhou acquired global rights to Cevira®, a treatment for HPV-induced precancerous cervical lesions, from Photocure of Oslo in an agreement worth up to $73 million. Cevira® is a photodynamic drug-device combination that treats cervical dysplasia by placing the device on the patient’s cervix during an office procedure. Asieris will pay a $5 million signing fee, with $54 million for milestones in China, US and EU development, and $14 million for approval of a second China indication.
Source: China Biotoday
